Search | Clinical Trials Finder

Conditions: Sleep Apnea, Obstructive, Sleep Disorder, Sleep Apnea Syndromes, Sleep Disturbance
Interventions: Home sleep apnea test, PSG; Diagnostic Test
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 12 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: B-cell Malignancies
Interventions: AZD5492; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 10
States / cities: La Jolla, California • Boston, Massachusetts • Rochester, Minnesota + 6 more

Conditions: Otolaryngological Surgery
Interventions: Cuff ETT; Device
Lead sponsor: Kris Jatana; Other
Eligibility: Up to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)
Interventions: N-Acetyl-L-Leucine, Placebo; Drug · Other
Lead sponsor: IntraBio Inc; Industry
Eligibility: 4 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts • Houston, Texas

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions: ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor, T-cell replete HSCT from a related, haploidentical donor; Biological · Drug · Procedure
Lead sponsor: Kiadis Pharma; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 12
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 8 more

Conditions: Hepatocellular Carcinoma
Interventions: AZD9793 Intravenous (IV) monotherapy, AZD9793 Subcutaneous (SC) monotherapy; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: La Jolla, California • Los Angeles, California • Baltimore, Maryland + 4 more

Conditions: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: JNJ-80948543; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Duarte, California • New York, New York • Nashville, Tennessee + 3 more

Conditions: Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions: Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan, CliniMACS CD34 Reagent System, Tacrolimus, Cyclophosphamide, Plerixafor, Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent, Thiotepa, Mycophenolate Mofetil (MMF), Ruxolitinib, Sirolimus; Drug · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Sleep Apnea, Obstructive
Interventions: Adenotonsillectomy, Observation alone / no intervention; Procedure · Other
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 3 Years to 16 Years
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Obesity, Childhood, Cancer, Survivorship
Interventions: NOURISH-T+, Brief NOURISH-T+; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 5 Years to 14 Years
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Gainesville, Florida • Miami, Florida + 6 more

Conditions: Obstructive Sleep Apnea
Interventions: Ketorolac, Standard of Care; Drug
Lead sponsor: Emory University; Other
Eligibility: 2 Years to 18 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: PTSD, Firearm Injury, Suicide Prevention, Firearm Safety
Interventions: Project Safe Guard - Trauma, Project Safe Guard; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes Mellitus
Interventions: Allogenic Human Islet Cells, Immunosuppressive Agents, Gastrin 17; Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 68 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Advanced Malignant Solid Tumor
Interventions: RPTR-1-201, PD-1 / PD-L1 monoclonal antibody; Drug
Lead sponsor: Repertoire Immune Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Adenotonsillectomy, Post-operative Analgesia, Opioid Use
Interventions: Oxycodone, Ibuprofen, Acetaminophen; Drug
Lead sponsor: David Chi, MD; Other
Eligibility: 3 Years to 17 Years
Enrollment: 268 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Semantic Dementia
Interventions: Verdiperstat; Drug
Lead sponsor: Peter Ljubenkov, MD; Other
Eligibility: 18 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: San Francisco, California • Chicago, Illinois • Rochester, Minnesota + 2 more

Conditions: Acute Myeloid Leukemia, Advanced Myelodysplastic Syndromes
Interventions: Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Sarcoma
Interventions: graft versus host disease prophylaxis/therapy, busulfan, melphalan, thiotepa, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 40 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Circadian Dysrhythmia
Interventions: Jawbone UP4; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 5 Years to 10 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sleep Apnea, Obstructive, Tonsillectomy, Adenoidectomy, Postoperative Complications
Interventions: Caffeine, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 30 Months to 18 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Castration-resistant Prostatic Neoplasms
Interventions: Pasritamig, Placebo, Best Supportive Care (BSC), JNJ-87189401; Biological · Other · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 54
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 43 more

Conditions: Prostatic Neoplasms
Interventions: JNJ-78278343, JNJ-95298177, JNJ-87189401; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Sarasota, Florida • New York, New York • Cleveland, Ohio + 1 more

Conditions: Down Syndrome, Sleep Disordered Breathing
Interventions: Adenotonsillectomy; Procedure
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 3 Years to 13 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Ann Arbor, Michigan • Cincinnati, Ohio • Cleveland, Ohio + 3 more

Conditions: Obstructive Sleep Apnea, Snoring
Interventions: Adenotonsillectomy (AT) - removal of adenoids and tonsils, Watchful Waiting; Procedure · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 5 Years to 9 Years
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 6
States / cities: Boston, Massachusetts • St Louis, Missouri • New York, New York + 3 more

Search by objective public record fields.

HSAT for OSA Management in Children

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Endotracheal Tube Intracuff Pressure and Leak Around the Cuff During Retractor Placement for Adenotonsillectomy

A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer

First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Effect of Adenotonsillectomy on Quality of Life in Children With Mild Obstructive Sleep Apnea

NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors

Effect of Ketorolac on Post Adenotonsillectomy Pain

Project Safe Guard-Trauma

Islet Cell Transplant for Type 1 Diabetes

An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

Non-opioids for Analgesia After Adenotonsillectomy in Children

Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology

Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors

Post Discharge Circadian Rhythms Post Adenotonsillectomy

The Effect of Caffeine on Postextubation Adverse Respiratory Events in Children With Obstructive Sleep Apnea (OSA).

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

Healthy Sleep for Children With Down Syndrome

Childhood Adenotonsillectomy Study for Children With OSAS